Enveric Biosciences announced it has received a Notice of Allowance from the United States Patent and Trademark Office for a patent application related to its EVM301 Series of drug candidates. The patent application, titled "N-heterocycle substituted tryptamine derivatives and methods of using," covers compositions and methods of use for potential neuroplastogenic non-hallucinogenic molecules aimed at treating neuropsychiatric and addiction disorders. The company highlighted that its lead asset, EB-003, is designed to selectively engage both 5-HT₂A and 5-HT₁B receptors to provide fast-acting and durable antidepressant and anxiolytic effects, while minimizing hallucinogenic side effects.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251209210165) on December 09, 2025, and is solely responsible for the information contained therein.